Tag Archives: Ariad

January, 2017

  • 9 January

    Takeda to Acquire ARIAD Pharmaceuticals for $5.2 Billion

    CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of …

April, 2016

  • 15 April

    Ariad Presents Updated Phase 1/2 Data on its NSCLC Drug

    GENEVA & CAMBRIDGE, Mass.–(BUSINESS WIRE)–ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), from an ongoing Phase 1/2 trial. This report includes updated data on the …